Last reviewed · How we verify
ABSK061
At a glance
| Generic name | ABSK061 |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia (PHASE1, PHASE2)
- A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants (PHASE1)
- A Phase 2 Clinical Study of ABSK061 and ABSK043 (PHASE2)
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABSK061 CI brief — competitive landscape report
- ABSK061 updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI